23.06.17: Not intended for U.S. and UK Media

Bayer Receives Positive CHMP Opinion for regorafenib for the Second-Line Systemic Treatment of Liver CancerPositive opinion based on data from the Phase III RESORCE study, in which regorafenib demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) / Approval could provide first treatment advance in nearly a decade / Final decision from the European Commission anticipated within the next two monthsmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news